U.S. Court of Appeals Rejects Donald Trump's Request to Postpone Tariff Refunds
Svmuu News: The U.S. Supreme Court previously ruled that most of the tariff measures imposed by President Donald Trump’s administration were invalid. The Department of Justice subsequently filed an appeal with the federal appeals court, requesting an additional 90-day grace period to allow the executive and legislative branches time to consider their options, resulting in a total delay of approximately four months.However, the U.S. Court of Appeals for the Federal Circuit has rejected the Department of Justice’s request, meaning the next steps in the tariff refund process can proceed swiftly. This ruling by the federal appeals court clears the way for the U.S. Court of International Trade, a lower court, to initiate legal proceedings related to tariff refunds.According to estimates by Department of Justice attorneys, the refund process could take several years to complete. Following the Supreme Court’s ruling, hundreds of new companies have filed tariff refund lawsuits, bringing the total number of tariff cases facing the Donald Trump administration to over 2,000.
Source:Odaily · Source Link
Disclaimer: This content reflects only the author’s personal views and does not constitute any investment or financial advice. If you discover any content that violates regulations,Click to Report
24H Trending
-
1
Billionaire investor Chase Coleman’s Tiger Global fund disclosed in its latest 13F filing that its top five growth stocks are all focused on AI infrastructure, including TSMC, NVIDIA, Amazon, Meta, and Google.
-
2
Will the BEAM token go to zero? Could it rise to $1,000? An in-depth analysis of the Beam network and its market prospects
-
3
What Is CVP? An In-Depth Analysis of the PowerPool Ecosystem and the Investment Value of Its Token, CVP
-
4
Analysis of CRYSTAL’s Value and Investment Potential: An Examination of Multiple Projects and Risk Assessment
-
5
Analysis: The State Street Healthcare ETF (XLV) has an expense ratio of 0.08% and a diversified portfolio, while the Invesco Biotechnology ETF (PBE) has an expense ratio of 0.58% and focuses on small-cap stocks; PBE is up 10.2% year-to-date, outperforming XLV.
-
6
Ethereum Recent Rebound: Price Breaks Above $1,970, but Multiple Risks Remain
-
7
QUARTZ Coin Analysis: An Overview of the Sandclock (QUARTZ) and Unique Network’s Quartz (QTZ) Projects
-
8
What Is JGN? Analysis of the JGN (Sword Saint Coin) Project’s Positioning, Features, and Value
-
9
Iran-linked exchange Shelbit allegedly sent $676 million to Binance in sanctions-evasion operation, Reuters reports
-
10
NVIDIA and AMD: The Two Giants of AI Computing Power in 2026—An Analysis of Market Dynamics, Financial Performance, and Opportunities for Transition into Cryptocurrency Mining
Markets Today
Recommended Reading









